About
CellRep uses AI-driven drug discovery to develop small molecule compounds that rejuvenate immune cells ex vivo, enhancing the efficacy of CAR-T cell therapies against solid tumors without genetic modification.
Explore CellRep's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.